BioSpace News Archive

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at two upcoming investor conferences.

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), today announced that Jasbir S. Seehra, Ph.D, President and Chief Executive Officer, and Keith Regnante, Chief Financial Officer, will participate in a fireside chat presentation at the Morgan Stanley 20th Annual Global Healthcare Conference.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland to enable an investigator-initiated open label Phase II clinical trial.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 15/551,284.

MicroGEM, a Virginia-based life sciences and molecular diagnostics company,and Workflow Services by ImageMover, a healthcare software company that provides solutions to capture point-of-care medical data through provider-focused digital workflows, have announced their partnership to streamline COVID-19 test result workflow.